Acasti Pharma (ACST) Receives Media Impact Score of 0.02
Press coverage about Acasti Pharma (NASDAQ:ACST) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acasti Pharma earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.4276016085794 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Acasti Pharma (NASDAQ ACST) traded down $0.04 during trading hours on Tuesday, hitting $0.95. 390,557 shares of the stock traded hands, compared to its average volume of 446,593. The company has a market capitalization of $14.77, a P/E ratio of -1.20 and a beta of 1.49. Acasti Pharma has a 52-week low of $0.84 and a 52-week high of $3.36.
Several equities analysts have recently commented on the stock. Benchmark assumed coverage on shares of Acasti Pharma in a research note on Friday. They set a “buy” rating and a $7.00 price objective for the company. ValuEngine raised shares of Acasti Pharma from a “sell” rating to a “hold” rating in a research note on Monday, November 20th.
COPYRIGHT VIOLATION WARNING: “Acasti Pharma (ACST) Receives Media Impact Score of 0.02” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/acasti-pharma-acst-receives-media-impact-score-of-0-02/1800226.html.
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.